Prostate cancer diagnosis and staging errors

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This review is analyzing advantages and disadvantages of basic methods for prostate cancer diagnostics and staging. Latest high-tech staging methods and nomograms are demonstrated. Causes of the errors occurring during prostate cancer diagnosing and staging are examined.

Full Text

Restricted Access

About the authors

Salman Hasunovich Al-Shukri

St.-Petersburg State I. P. Pavlov Medical University

Email: al-shukri@mail.ru
doctor of medical science, professor, head of the department. Department of Urology

Sergey Yuryevich Borovets

St.-Petersburg State I. P. Pavlov Medical University

doctor of medical science, senior researcher. Department of Urology

Maksim Aleksandrovich Rybalov

St.-Petersburg State I. P. Pavlov Medical University

postgraduate. Department of Urology

References

  1. Чиссов В. И., Русаков И. Г. Заболеваемость раком предстательной железы в Российской Федерации // Экспериментальная и клиническая урология. — 2011. — № 2–3. — С. 6–7.
  2. Quinn M., Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons // B. J. U. Int. — 2002. — Vol. 90, N 2. — P. 162–173.
  3. Ilic D., O’Connor D., Green S., Wilt T. J. Screening for prostate cancer: a Cochrane systematic review // Cancer Causes Control. — 2007. — Vol. 18, N 3. — P. 279–285.
  4. Andriole G. L., Crawford E. D., Grubb R. L. 3rd. et al. Mortality results from a randomized prostate-cancer screening trial // N. Engl. J. Med. — 2009. — Vol. 360, N 13. — P. 1310–1319.
  5. Schröder F. H., Hugosson J., Roobol M. J. et al. Screening and prostate-cancer mortality in a randomized European study // N. Engl. J. Med. — 2009. — Vol. 360, N 13. — P. 1320–1328.
  6. Schröder F. H., van der Maas P., Beemsterboer P. et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer // J. Natl. Cancer Inst. — 1998. — Vol. 90, N 23. — P. 1817–1823.
  7. Semjonow A., Brandt B., Oberpenning F. et al. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values // Prostate. — 1996. — Suppl. 7. — P. 3–16.
  8. Thompson I. M., Pauler D. K., Goodman P. J. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter // N. Engl. J. Med. — 2004. — Vol. 350, N 22. — P. 2239–2246.
  9. Heidenreich A., Bellmunt J., Bolla M. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease // Eur. Urol. — 2011. — Vol. 59, N 1. — P. 61–71.
  10. Carter H. B., Pearson J. D., Metter E. J. et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease // JAMA. — 1992. — Vol. 267, N 16. — P. 2215–2220.
  11. Schmid H.-P., McNeal J. E., Stamey T. A. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume // Cancer. — 1993. — Vol. 71, N 6. — P. 2031–2040.
  12. Catalona W. J., Partin A. W., Slawin K. M. et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicentre clinical trial // JAMA. — 1998. — Vol. 279, N 19. — P. 1542–1547.
  13. Deras I. L., Aubin S. M., Blase A. et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome // J. Urol. — 2008. — Vol. 179, N 4. — P. 1587–1592.
  14. Eichler K., Hempel S., Wilby J. et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review // J. Urol. — 2006. — Vol. 175, N 5. — P. 1605–1612.
  15. Donovan J., Hamdy F., Neal D. et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study // Health Technol. Assess. — 2003. — Vol. 7, N 14. — P. 1–32.
  16. Матвеев Б. П. Клиническая онкоурология. — М.: Вердана, 2003. — 717 с.
  17. Spigelman S. S., McNeal J. E., Freiha F. S., Stamey T. A. Rectal examination in volume determination of carcinoma of the prostate: clinical and anatomical correlations // J. Urol. — 1986. — Vol. 136, N 6. — P. 1228–1230.
  18. Partin A. W., Carter H. B., Chan D. W. et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumour differentiation, tumour volume and benign hyperplasia // J. Urol. — 1990. — Vol. 143, N 4. — P. 747–752.
  19. Hudson M. A., Bahnson R. R., Catalona W. J. Clinical use of prostate specific antigen in patients with prostate cancer // J. Urol. — 1989. — Vol. 142, N 4. — P. 1011–1017.
  20. Enlund A., Pedersen K., Boeryd B., Varenhorst E. Transrectal ultrasonography compared to histopathological assessment for local staging of prostatic carcinoma // Acta Radiol. — 1990. — Vol. 31, N 6. — P. 597–600.
  21. Sauvain J. L., Palascak P., Bourscheid D. et al. Value of power and 3D vascular sonography as a method for diagnosis and staging of prostate cancer // Eur. Urol. — 2003. — Vol. 44, N 1. — P. 21–30; discussion 30–31.
  22. Zalesky M., Urban M., Smerhovský Z. et al. Value of power Doppler sonography with 3D reconstruction in preoperative diagnostics of extraprostatic tumor extension in clinically localized prostate cancer // Int. J. Urol. — 2008. — Vol. 15, N 1. — P. 68–75; discussion 75.
  23. Fuchsjager M., Shukla-Dave A., Akin O. et al. Prostate cancer imaging // Acta Radiol. — 2008. — Vol. 49, N 1. — P. 107–120.
  24. Simmons L. A., Autier P., Zát'ura F. et al. Detection, localisation and characterisation of prostate cancer by prostate HistoScanning (™) // B. J. U. Int. — 2012. — Vol. 110, N 1. — P. 28–35.
  25. Cooperberg M. R., Freedland S. J., Pasta D. J. et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy // Cancer. — 2006. — Vol. 107, N 10. — P. 2384–2391.
  26. Partin A. W., Mangold L. A., Lamm D. M. et al. Contemporary update of the prostate cancer staging nomograms (Partin Tables) for the new millennium // Urology. — 2001. — Vol. 58, N 6. — P. 843–848.
  27. Whitmore W. F. Jr. Natural history and staging of prostate cancer // Urol. Clin. North Am. — 1984. — Vol. 11, N 2. — P. 205–220.
  28. Wolff J. M., Ittel T. H., Borchers H. et al. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase // Anticancer Res. — 1999. — Vol. 19, N 4A. — P. 2653–2655.
  29. Rana A., Karamanis K., Lucas M. G., Chisholm G. D. Identification of metastatic disease by T category, Gleason score and serum PSA level in patients with carcinoma of the prostate // Br. J. Urol. — 1992. — Vol. 69, N 3. — P. 277–281.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Al-Shukri S.H., Borovets S.Y., Rybalov M.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ №ФС77-65570 от 04 мая 2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies